Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidofludimus Calcium in Primary Sclerosing Cholangitis
NCT03722576Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vidofludimus calcium in Primary Sclerosing Cholangitis (PSC). Primary endpoint: Positive Outcome Measured by Combination of Serum Alkaline Phosphatase and Aspartate Aminotransferase at 24 weeks. Started Jun 2019; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03722576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722576.